Report Details
- what commercial prospects for those technologies in medicine?
In 2010, the stem cells market stands on the brink of technological and commercial breakthroughs, our new study explains. For the first time, pharmaceutical companies are beginning to invest significantly in the drive to create new treatments based on embryonic and adult stem cells. As this research gathers pace, with clinical trials commencing, the potential of stem cells in medicine may relatively soon be fulfilled. Results in animals indicate that stem cells may provide treatment options for a range of disorders and restorative applications including multiple sclerosis, diabetes, Parkinson's disease, Alzheimer's disease, spinal cord injury, blindness, immune system disorders and cardiovascular disease.
Stem Cells - The Hype and the Hope 2010-2025 provides an analytical overview of this burgeoning sector, with technologies and commercial potential discussed and forecasted. The sector will gather momentum as stem cell therapies start to emerge from the R&D pipeline from this decade onwards. In this report we assess the disease areas in which stem cell therapies are most likely to emerge, with overviews of the commercial and academic research being carried out in subsectors of healthcare. We analyse the short-, medium- and long-term prospects for stem cell breakthroughs in disease areas, providing the information that you require.
Our new report also provides a review of leading companies that currently seek to harness stem cell technologies. The research areas of each company are profiled, with discussion of the approaches being used. Some organisations are developing scalable therapies with allogeneic stem cells, while others investigate personalised treatments using autologous stem cells. Other organisations pursue research in the embryonic stem cells field, which has opened up in the US, with fewer obstacles and greater funding opportunities available since 2009. Some companies already generate revenues from stem cells by carving out market niches in stem cell supply, such as stem cells for drug development and toxicity assays, or services such as stem cell banking in umbilical cord blood. We analyse the main divisions of the market, providing revenue forecasts for 2010 to 2025.
Comprehensive analysis of the global stem cells market
Stem Cells - The Hype and the Hope 2010-2025 examines that sector through a comprehensive review of information sources. We use primary and secondary research. This report provides unique sales forecasts, market share analyses, discussions of R&D pipeline developments and analyses of commercial drivers and restraints, including SWOT analysis. There are comprehensive tables and figures, as well as four interviews with experts. The result is a detailed market- and industry-centred study, with analyses and informed opinion to benefit your work.
Why you should buy Stem Cells - The Hype and the Hope 2010-2025
This report gives you the following benefits in particular:
• You will receive a comprehensive analysis of the prospects for stem cells from 2010 to 2025, including predicted revenues, growth rates and other data for the overall market and its main divisions
• You will find out where the market is heading - technologically and commercially - from the present onwards, both for the global market and for leading national markets
• You will discover prospects for leading companies and therapy areas, with predictions of where main breakthroughs are likely to come from 2010 to 2025
• You will identify significant R&D developments as well as up-and-coming technologies and products
• You will discover expert opinion from our interview-based survey, with discussion of the present and future of stem cells in medicine
• You will assess the commercial drivers, restraints, competition and opportunities influencing the global stem cell sector.
Our research shows that stem cells hold the potential to change medicine in decades to come, with benefits to healthcare stakeholders starting to appear during our forecast period, 2010 to 2025. We separate the real potential from the wishful thinking in this complex field.
You can obtain this report today
Nobody with an interest in healthcare biotechnology should overlook our new study on stem cells. We predict that revenue streams will commence and increase during our forecast period. With rising demand for novel therapies and many unmet clinical needs remaining, the stem cells industry and market hold potential for high revenues and continuous innovation. Do you want to be aware of those opportunities? You can stay ahead by ordering our new report today.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
Table of Contents
1. Executive Summary
1.1 Stem Cells Market Review
1.2 Crucial Aspects of the Stem Cells Market
1.3 Aims, Scope and Format of this Report
1.3.1 Speculative Aspects of Assessing the Stem Cell Field
1.3.2 Chapter Outline
1.4 Research and Analysis Methods
2. Stem Cells: An Introduction
2.1 Stem Cells in 2010: Overview of the Sector
2.2 The Basics: What Are Stem Cells?
2.3 Stem Cell Potency
2.3.1 Totipotency
2.3.2 Pluripotency
2.3.3 Multipotency
2.3.4 Oligopotency
2.3.5 Unipotency
2.3.6 Stem Cells and Progenitor Cells
2.4 Embryonic Stem Cells
2.4.1 Abortion Debates, IVF, and Embryonic Stem Cells
2.4.2 Harvesting Human Eggs
2.5 Adult Stem Cells
2.5.1 Sources of Adult Stem Cells
3. Issues Affecting the Stem Cells Market, 2010
3.1 Strengths
3.1.1 Stem Cells Have Great Therapeutic Potential
3.1.2 Stem Cells Could Revolutionise Our Understanding of Disease
3.1.3 Animal Models Yield Impressive Results
3.1.4 Stem Cells Already Have Some Therapeutic Applications
3.1.5 The Stem Cells Field Has Strength in Numbers
3.1.6 Discoveries Are Being Made at a Rapid Rate
3.1.7 Adult Stem Cells: Fewer Ethical Controversies
3.1.8 Many Governments Support Adult Stem Cell Research
3.1.9 Stem Cells Have Proven Uses and Marketability Beyond Their Directly Therapeutic Applications
3.1.10 The Market Offers Multiple Business Models
3.2 Weaknesses
3.2.1 Therapies Take Time
3.2.2 Stem Cells and Cancer
3.2.3 The Safety-First Approach
3.2.4 Embryonic Stem Cell Supply Problems
3.2.5 Business Model Problems with Autologous Therapies
3.2.6 Donor Rejection Risk with Allogeneic Therapies
3.2.7 The Research Field is Fragmented
3.2.8 The IP Minefield
3.2.9 Government Money is Required: Little Venture Capital - Yet
3.2.10 Problems Adapting Pharmaceutical Business Model to Stem Cells
3.3 Opportunities
3.3.1 Therapies: Almost Anything Could Happen
3.3.2 The Attractions of the Stem Cells Market
3.3.3 Asia Harnesses Stem Cells Opportunities
3.3.3.1 China: Favourable Regulations
3.3.3.2 Japan: Liberal hESC Policy
3.3.3.3 Singapore: Advanced and Prominent
3.3.3.4 South Korea: Stem Cells a National Priority
3.3.3.5 India: First Official Research Hub Opened in 2009
3.3.3.6 Israel: at The Forefront
3.3.3.7 Gulf Countries: Funding Stem Cell Research
3.3.4 Adipose Tissue Opportunities for IPSCs
3.3.5 Beyond Pluripotency
3.3.6 Pharmaceutical Laws Do Not Apply to Stem Cell Therapies
3.3.7 Unique Disease Modelling Possibilities With IPS Cells
3.3.8 High Net-Worth Individuals: A Possible Source of Stem Cell Capital
3.3.9 The Opportunity to Get There First
3.3.10 Public Perception of Stem Cells Represents an Opportunity
3.4 Threats
3.4.1 The Risks of the Regulatory Environment
3.4.1.1 North America
3.4.1.2 Europe
3.4.2 Lack of Embryonic Stem Cell Diversity in US Research
3.4.3 Not Everyone Can Succeed in The Stem Cells Market
3.4.4 The Risk of Public Disenchantment
3.4.5 High-Profile Failures in Stem Cell Supply
3.4.6 High-Profile Failures in Stem Cell Therapies
3.4.7 Scare Stories and Perception Problems
3.4.8 Economic Instability
3.4.9 Market Fluidity is a Threat
3.4.10 Are Stem Cells Too Revolutionary for the Existing Pharmaceuticals Model?
4. The Stem Cell Market in 2010
4.1 The Stem Cell Market Was Worth Around $2.8bn in 2009
4.1.1 Where The Money is: Divisions of the Stem Cells Market in 2010
4.2 Stem Cell Therapies
4.2.1 Existing Stem Cell Therapies Market
4.2.2 Diseases Treated With Adult Stem Cells In 2010
4.2.3 Bone Marrow Transplants
4.2.3.1 The Transplant Process
4.2.3.2 The Results
4.2.4. Peripheral Blood Stem Cell Transplants
4.2.5 Cord Blood Stem Cell Transplants
4.2.6 Allogeneic Transplants vs. Autologous Transplants
4.2.6.1 Allogeneic Transplants are Better for Killing Cancer
4.2.6.2 The Problem with Allogenic Transplants: Graft-versus-Host Disease and Host-versus-Graft Disease
4.2.6.3 Saviour-Siblings: Stem Cells from a Sibling, Created or Chosen to be a Saviour
4.2.6.4 UK Cases and Rules on Saviour Siblings
4.2.7 Other Surgery Involving Stem Cells
4.2.8 Osteocel and other Bone Regeneration Products
4.2.9 Stem Cells and Regenerative Medicine
4.2.9.1 Organogenesis
4.2.9.2 Stem Cell Therapeutics
4.2.9.3 CEL-SCI Corporation
4.2.9.4 Osteotech
4.2.9.5 RegeneRx
4.2.9.6 RTI Biologics
4.2.9.7 Biomimetic Therapeutics
4.2.9.8 Fibrocell
4.2.10 Stem Cell Cosmetics
4.2.10.1 Breast Enhancement
4.2.10.2 Topical "Stem Cell" Preparations
4.2.11 Unregulated Stem Cells Therapies
4.3 Stem Cell Services
4.3.1 The Market for Stem Cell Services
4.3.2 Some of the Companies in the Stem Cell Services Market
4.3.2.1 Cellular Dynamics International: Cardiomyocyte Technology
4.3.2.2 Fate Therapeutics: Stem Cells for Drug Discovery
4.3.2.3 International Stem Cell Corporation: Parthenogenetic Cell Line Bank
4.3.2.4 Axiogenesis: Research Tools
4.3.2.5 Vitro Biopharma: Longer-Lasting Cell Line Expansion Periods
4.3.2.6 CellCyte Genetics: Expansion Bioreactor
4.3.2.7 MultiCell Technologies: Liver Stem Cell Lines
4.3.2.8 Stemgent: Stem Cell Scientists
4.3.2.9 Regenetech: Stem Cell Expansion Leaders
4.3.2.10 Pfizer/Novocell: Pancreatic Cell Lines
4.3.2.11 Biotime: 200+ Patent Portfolio
4.3.2.12 StemLifeLine: Embryonic Stem Cells Without Embryo Destruction?
4.3.2.13 Stem Cell Innovations (SCI): PluriCells Platform
4.3.2.14 HyClone/Thermo Fisher Scientific: 40 Years of Cell Culture Products
4.3.2.15 Merck/Calibochem/Stem Cell Sciences: Drug Screening Assays
4.3.2.16 Stemride International Limited (SIL) and Reproductive Genetics Institute, Chicago: Normal and Abnormal Cell Lines
4.3.2.17 ES Cell International, Singapore: Hoping for the First Marketed Product Including Embryonic Stem Cells
4.3.2.18 StemCell Technologies: ES Cells and Cell Culture Supplies
4.3.2.19 Bio-Matrix Scientific Group: Cryopreservation
4.4 Blood Banking
4.4.1 Biological Insurance: Private Blood Banking
4.4.2 Umbilical Cord Banking: The Controversies
4.4.2.1 US Oversight of Cord Blood Stem Cells
4.4.3 The Market for Blood Banking
4.4.4 Companies in the Field
4.4.4.1 Cord Blood America: Looking Towards the Chinese Market
4.4.4.2 ViaCord: 145,000 Blood Units in Storage
4.4.4.3 Cryo-Cell International: The First Cord Blood Bank
4.4.4.4 Stem Cell Authority: Exclusive Stem Cells
4.4.4.5 LifebankUSA: Placenta-Cord Banking
5. The New Stem Cell Therapies I: Companies and Business Models
5.1 In Search of a Stem Cells Business Model
5.1.1 Embryonic or Adult?
5.2 Stem Cell Companies in the Media Spotlight
5.2.1 Towards the First Human Trials of Embryonic Stem Cells
5.2.2 Adult Stem Cells: Collaborations with Pharmaceutical Giants
5.3 Embryonic Stem Cells
5.3.1 Geron: First Embryonic Stem Cell Trial
5.3.1.1 Geron and GE Healthcare
5.3.2 Advanced Cell Technology (ACT)
5.3.2.1 Competition for ACT in Macular Degeneration Treatment
5.3.2.2 ACT Deals with Other Companies
5.3.3 Novocell: Looking to Follow Geron and ACT in Embryonic Stem Cells Trials
5.3.3.1 Novocell's Collaborations with Pharmaceutical Leaders
5.3.4 CellCure Neurosciences
5.3.5 Royan Institute (Tehran)
5.3.6 Reliance Life Sciences, India
5.4 Adult Stem Cell Therapies: Allogeneic
5.4.1 Osiris: First to Market with Stem Cells
5.4.1.1 Osiris and NuVasive
5.4.1.2 Osiris and Genzyme
5.4.1.3 Prochymal: Great Promise but How is Work Shaping Up?
5.4.1.4 What Next for Prochymal?
5.4.2 Athersys
5.4.2.1 Multistem: an Off-The-Shelf Allogeneic Stem Cell Therapy
5.4.3 StemCells
5.4.4 MediStem (MediStem Laboratories, Inc.)
5.4.5 ReNeuron
5.4.6 Pluristem Therapeutics
5.4.7 Amstem International (Stem Cell Therapy International/Histostem)
5.4.8 Neuralstem
5.4.9 Garnet BioTherapeutics/Neuronyx
5.4.10 HepaLife Technologies
5.5 Adult Stem Cells: Autologous Therapies
5.5.1 Opexa Therapeutics
5.5.1.1 Tovaxin
5.5.2 Cellerix: Ontaril has EMEA Orphan Drug Status
5.5.3 Aastrom Biosciences
5.5.4 Bioheart
5.5.5 Cardiogenesis: Autologous Medical Devices
5.5.6 BrainStorm Cell Therapeutics
5.5.7 Cytori Therapeutics
5.5.8 TCA Cellular Therapy
5.5.9 Autologous Cell Storage
5.5.9.1 LifeStem: Two Sources of Stem Cells Preserved
5.5.9.2 Neostem: Success with Bone Marrow Stem Cell Storage
5.5.9.3 Thermogenesis: Autologous Cryopreservation
5.5.9.4 Biogenea-CellGenea: Leading Stem Cell Research Facility in the EU
6. The New Stem Cell Therapies II: Indications
6.1 The Growth of the Stem Cells Market to 2025
6.2 Near-Term Indications
6.2.1 Cancer
6.2.1.1 Cancer Stem Cells
6.2.2 Immune Disorders
6.2.3 Eye Diseases
6.2.4 Orthopaedics
6.2.5 Diabetes
6.2.6 Other Likely Near-Term Indications
6.2.6.1 Acute Radiation Syndrome
6.3 Cardiovascular Diseases
6.4 Brain and Central Nervous System Diseases
6.4.1 Amyotrophic Lateral Sclerosis (ALS, Lou Gherig's Disease)
6.4.2 Multiple Sclerosis
6.4.3 Alzheimer's Disease
6.4.4 Cerebral Palsy
6.4.5 Pelizaeus-Merzbacher Disease (PMD)
6.4.6 Parkinson's Disease
6.4.7 Spinal Cord Injury
6.5 Growing Organs
6.6 Other Possible Indications for Stem Cells
6.6.1 Autism
6.6.2 HIV and Other Viral Diseases
6.6.3 Fertility Treatment
7. Interviews with Experts
7.1 Dr Johan Luthman, Merck Serono
7.1.1 Difficulties of Translational Medicine
7.1.2 Differences Between Technology and Media Perceptions
7.1.3 Confusion in the Media
7.1.4 Stem Cells and Neurologic Disorders
7.1.4.1 Which Neurological Disorders will be Treated First?
7.1.4.2 Multiple Sclerosis
7.1.5 Why Stem Cell Results Take a Long Time
7.1.6 When Stem Cell Therapies Will Reach the Market
7.1.7 The Distinction between Regenerative Medicine and Stem Cell Therapies
7.2 Dr Stephen Minger, Wolfson Centre for Age-Related Diseases, King's College London
7.2.1 On Whether Adult or Embryonic Stem Cells Should Receive More Funding/Support
7.2.2 Cord Blood and Embryonic Stem Cells
7.2.3 The Need for More Immunological Assays
7.2.4 How Long Until there are Human Stem Cell Therapies?
7.2.5 Cord Blood as a Source of Stem Cells
7.2.6 Private Cord Blood Banking
7.2.7 Therapeutic Cloning
7.2.7.1 Therapeutic Cloning and Tissue Type Cell Lines
7.2.8 Promising and Unusual Immunological Properties of Embryonic Stem Cells
7.2.9 Mesenchymal Stem Cells and Inflammation
7.2.10 On the Use of Foreskin Fibroblasts
7.3 Gregory Bonfiglio, Proteus Venture Partners
7.3.1 On the Terms "Stem Cell Therapy" and "Regenerative Medicine"
7.3.2 On "Near Term" Applications
7.3.3 Value-Creation Curve for Venture Capital in Stem Cells
7.3.4 On There Being No Known Limits on Stem Cell Possibilities
7.3.5 On Stem Cells in 25 Years
7.3.6 Funding as a Primary Limitation?
7.3.7 Stem Cells in Multiple Sclerosis and Diabetes Type 1
7.3.8 Cord Blood
7.3.9 Extracellular Matrixes
7.3.10 Disease-Specific Cell Lines
7.3.11 Adult vs. Embryonic Stem Cells
7.3.12 Capital for Stem Cell and Regenerative Medicine Research
7.4 Josephine Quintavalle, Founder of Comment on Reproductive Ethics (CORE)
7.4.1 Embryonic Stem Cells and Dehumanisation
7.4.2 HFEA Regulation on Embryo Destruction
7.4.3 Economics and Scientific Effectiveness
7.4.4 Cord Blood
7.4.5 Adult Stem Cell Therapies and the Economics of Therapy
7.4.6 Public, Private and Private/Public Cord Blood Banks
7.4.7 International Studies and International Communication
8. Conclusions
8.1 The Stem Cell Market in 2010 is Small, But Will Grow Rapidly
8.2 The Stem Cell Therapies Market is on The Brink of Significant Growth
8.3 Induced Pluripotent Adult Stem Cells May Revolutionise the Market
8.4 The Sector Has Marked Uncertainties, But Many Opportunities
List of Tables
Table 2.1 Potency and Source of Stem Cells
Table 2.2 Germ Layers and Their Associated Types of Cells and Organs
Table 3.1 SWOT Analysis of the Stem Cells Sector, 2010
Table 4.1 Bone Marrow Transplants: Sales Forecast ($m), 2010-2025
Table 4.2 Some Diseases That Have Been Treated With Adult Stem Cells, 2010
Table 4.3 Osteocel Products: Sales Forecast ($m), 2010-2015
Table 4.4 Some Companies in the Regenerative Medicine Sector, 2010
Table 4.5 Stem Cell Services: Sales Forecast ($m), 2010-2025
Table 4.6 Some Companies in the Stem Cell Services Market, 2010
Table 4.7 Cord Blood Banking: Sales Forecast ($m), 2010-2025
Table 4.8 Some Companies in the Cord Blood Banking Market, 2010
Table 5.1 Some Companies in the Embryonic Stem Cell Therapies Sector, 2010
Table 5.2 Some Companies in the Allogeneic Adult Stem Cell Therapies Sector, 2010
Table 5.3 Some Companies in the Autologous Adult Stem Cell Therapies Sector, 2010
Table 6.1 Stem Cell Therapies: Sales Forecast ($m), 2010-2025
Table 6.2 Total Stem Cells Market: Sales Forecast ($m), 2010-2025
Table 8.1 Total Stem Cells Market: Sales Forecast by Sector ($m), 2010-2025
List of Figures
Figure 4.1 Sectors of the Stem Cells Market: Sales ($bn), 2009
Figure 4.2 Bone Marrow Transplants: Sales Forecast ($m), 2010-2025
Figure 4.3 Osteocel Products: Sales Forecast ($m), 2010-2015
Figure 4.4 Stem Cell Services: Sales Forecast ($m), 2010-2025
Figure 4.5 Cord Blood Banking: Sales Forecast ($m), 2010-2025
Figure 6.1 Stem Cell Therapies: Sales Forecast ($m), 2010-2025
Figure 6.2 Total Stem Cells Market: Sales Forecast ($m), 2010-2025
Companies Listed
Aastrom Biosciences
Advanced Cell Technology
Aldagen
Alliance Technology Ventures
Amorcyte
AmStem International
Angioblast Systems
Anthony Nolan Trust
Assisted Human Reproductions Agency
AstraZeneca
Athersys
Australian Stem Cell Centre
Axiogenesis
AXM Pharma
Biogenea-CellGenea
Bioheart
Bio-Matrix Scientific Group
Biomimetic Therapeutics
BioTime
Boston Scientific Corporation
BrainStorm Cell Therapeutics
Bresagen
Burnham Institute for Medical Research, University of California
Calibochem
Canadian Institute of Health
Cardiogenesis Corp.
Casey Eye Institute
Cellartis
CellCure Neurosciences
CellCyte Genetics Corporation
Cellerix
Cellgene Corporation
Cellular Dynamics International
Cellular Engineering Technologies
Celprogen
CEL-SCI Corporation
Centocor Ortho Biotech
CHA Biotech
Children's Hospital of Orange County
Children's Hospital & Research Center in Oakland, California
Cleveland Clinic
Clinical Research Facility for Stem Cells and Regenerative Medicine, Hyderabad
Columbia University
Comment on Reproductive Ethics (CORE)
CorCell
Cord Blood America
Cord Blood Registry
Cordon Vital (CBR)
Cryo-Cell International
CyThera
Cytori Therapeutics
Diostech
Embryome Sciences
ES Cell International (Singapore)
European Medicines Agency (EMEA)
European Union Group on Ethics (EGE), The
EyeCyte
Fate Therapeutics
Fibrocell
Fisher Scientific
Foundation for Taxpayer and Consumer Rights, The
Gamida Cell
Garnet BioTherapeutics
GE Healthcare
Genzyme
Geron Corporation
Gladstone Institute of Cardiovascular Disease
GlaxoSmithKline
Hadasit Bio-Holdings
Hadassah University Hospital
Harvard Stem Cell Institute
Harvard University
HepaLife Technologies
Histostem
Human Fertilisation and Embryology Authority (HFEA, UK)
HyClone
Indiana University
International Society of Stem Cell Research
International Stem Cell Corporation
iPS Cells
Isolagen
Israeli Health Ministry
Johns Hopkins University
Johnson & Johnson
Korea Stem Cell Bank Co.
LifebankUSA
LifeCell India
Lifeline Cell Technology
LifeStem
London Breast Institute, Princess Grace Hospital
London Development Agency
London Regenerative Medicine Network (LRMN)
Maxim Biotech
Mayo Clinic
MedCell Biosciences
Medical College of Georgia
Medistem
Merck & Co.
Merck KGaA
Merck Serono
Mesoblast
Multicell Technologies
Muslim World League
Mytogen
NASA
National Institutes of Health (NIH, US)
National Health Service (NHS, UK)
National Tissue Engineering Center (Shanghai)
Neostem
Neuralstem
Neuronyx
Northwestern University
Novartis
Novartis Institutes for BioMedical Research (NIBR)
Novo Nordisk
Novocell
NuVasive
Opexa Therapeutics
Organogenesis
Orthofix
Osiris Therapeutics
OST Developpement
Osteotech
Patient Patent Foundation
Pfizer
Pluristem Therapeutics
Primogenix
ProLife Alliance, The
Proteus Venture Partners
Purdue University Indianapolis
Reeve-Irvine Research Centre
Regenetech
RegenRx
Reliance Life Sciences, India
ReNeuron
Reproductive Genetics Institute (Chicago)
RNL Bio
Roche
Royal Veterinary College, The
Royan Institute (Tehran)
RTI Biologics
Rutgers University
Safeguard Scientifics
SCP Vitalife Partners
Singapore Stem Cell Consortium
Stanford University
Stem Cell & Regenerative Medicine International
Stem Cell Authority
Stem Cell Innovations (SCI)
Stem Cell Products
Stem Cell Sciences
Stem Cell Therapeutics Corp.
Stem Cell Therapy International
Stem Cells Research Forum of India (SCRFI)
StemCell Technologies
StemCells
StemCells
Stemgent
StemLifeLine
Stemride International Limited (SIL)
SUNY Upstate Medical University
Suzhou Erye Pharmaceuticals
TCA Cellular Therapy
Tengion
Texas A&M University
The Food and Drug Administration (FDA)
Thermo Electron
Thermo Fisher Scientific
Thermogenesis Corp.
Transition Holdings
U.S. Army Institute of Surgical Research (USAISR)
U.S. Department of Defense
United States of America Patent and Trademark Office
University College London
University of Amsterdam
University of California at Irvine
University of California at San Diego
University of Edinburgh
University of Florida
University of Helsinki
University of Kyoto
University of Miami
University of Michigan
University of Oklahoma
University of Pittsburgh
University of South Florida
University of Texas, Medical Branch at Galveston
University of Virginia
University of Wisconsin
UT Southwestern Medical Center
Vantus
Veritas Corporation
VetCell Bioscience Limited
VetStem
ViaCord
Vitro Biopharma
Vitro Diagnostics
Voss Laboratories
Wake Forest University
Wisconsin Alumni Research Foundation (WARF)
Wolfson Centre for Age-Related Diseases (part of King's College, University of London)